Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models. Issue 7 (August 2018)

• Record Type: Journal Article
• Authors: Becquet, Mike; Laborde, Laurent; Texier, Celine; Sterker, Dario; Gschwind, Hans-Peter; Pfaar, Ulrike; Wartmann, Markus; O'Reilly, Terry M.; McSheehy, Paul M.
• Is Part Of: Anti-cancer drugs. Volume 29:Issue 7(2018)
• Publication Date: 2018-08
• Subjects: patupilone -- pharmacokinetics therapeutic index -- rats mini-pump -- tumour-xenograft mice; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000639
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Patupilone is a microtubule-targeted cytotoxic agent with clinical efficacy, but causes diarrhoea in more than 80% of patients. The efficacy and tolerability of patupilone delivered continuously by subcutaneous (s.c.) mini-pumps [(mini-pump dose (MPD)] or by intravenous bolus administration [intravenous bolus dose (IVBD)] were compared preclinically to determine whether the therapeutic index could be improved. The antiproliferative potency in vitro of patupilone was determined by measuring total cell protein. Tumours were grown s.c. in rats (A15) or nude mice (KB31, KB8511) or intracranially in nude mice (NCI-H460-Luc). Efficacy was monitored by measuring tumour volumes, bioluminescence or survival. Toxicity was monitored by body weight and/or diarrhoea. Total drug levels in blood, plasma, tissues or dialysates were quantified ex-vivo by liquid chromatography–mass spectroscopy/mass spectroscopy. Patupilone was potent in vitro with GI50s of 0.24–0.28 nmol/l and GI90s of 0.46–1.64 nmol/l. In rats, a single IVBD of patupilone dose dependently inhibited the growth of A15 tumours, but also caused dose-dependent body weight loss and diarrhoea, whereas MPD achieved similar efficacy, but no toxicity. In mice, MPD showed efficacy similar to that of IVBD against KB31 and KB8511 tumours, but with reduced toxicity. In a mouse intracranial tumour model, IVBD was more efficacious than MPD, consistent with patupilone concentrations in the brain. MPD provided constant plasma levels, whereas IVBD had very high C 0 / C min ratios of 70–280 (rat) or 8000 (mouse) over the dosing cycle. Overall, the correlation of plasma and tumour levels with response indicated that a Cave of at least GI90 led to tumour stasis. Continuous low concentrations of patupilone by MPD increased the therapeutic index in s.c. rodent tumour models compared with IVBD by maintaining efficacy, but reducing toxicity. Abstract : Supplemental Digital Content is available in the text.